Hengrui, Renfu, Huahai and other 19 pharmaceutical companies set up venture capital funds! They want to circle the land?

In 2016, 39 venture capital funds related to the pharmaceutical and health industry were established! In the past year, there have been 19 industrial funds initiated by pharmaceutical enterprises, among which there are many leaders in Hengrui pharmaceutical, humanwell pharmaceutical, Shangyao and other industries Why do so many industrial venture funds appear suddenly in one year? What resources will they seize? What is their investment direction? On May 3, Fosun Pharmaceutical released an announcement on subscription of private fund shares It said that Fosun industry, a wholly-owned subsidiary of Fosun Pharmaceutical, invested US $15 million to subscribe for the investment fund shares of PIF II, with the purpose of taking Partners Healthcare System, Inc (one of the largest medical groups in the United States, with 15 medical bidding and more than 80 research institutions including Massachusetts General Hospital, Brigham and women's Hospital, McLean and other Harvard Medical School teaching hospitals) commercialized research results Fosun Pharmaceutical is a representative enterprise in the investment field of domestic pharmaceutical industry In the past years, Fosun Pharmaceutical first relied on capital to promote the implementation of large-scale M & A in China, and then set up an investment fund to clean up goods in the global market, aiming at R & D and innovation, starting from "big" to "fine" Its operation mode in the field of capital is being used for reference by many enterprises in the industry In the past two years, a large number of pharmaceutical enterprises have established industrial funds According to the development stage of industrial fund, it is the establishment of M & A fund that is initially displayed in the industry at the phenomenal level From 2014 to 2015, the "investment institutions + listed companies" M & A fund mode was the most active form of fund performance At that time, industry M & a funds with health, medical and pharmaceutical themes emerged in succession According to incomplete statistics of e-medicine managers, by the end of 2015, there were more than 50 M & a funds initiated by pharmaceutical companies in the market At that time, Zhongyu capital alone cooperated with 14 pharmaceutical listed companies to establish M & a funds However, time has changed Around 2015, Chinese pharmaceutical listed companies were able to find some M & A targets in the priority space However, with the influx of large quantities of funds, the price of the targets has been rising continuously, and the high-quality targets have been acquired by many first wave M & A enterprises like Fosun Therefore, the industry phenomenon we can see is that these newly established M & a funds haven't made a big wave in the industry, and those enterprises that have already finished scavenging at home have begun to focus on the foreign market, so in the past two years, a large number of powerful listed companies have begun to kill the foreign market for M & A Now, it seems that the mode of establishing M & A fund is out of date Because the back-end is mature and there are fewer and fewer enterprises available for M & A, so in the past two years, industrial capital began to appear in the form of VC and PE, and began to seize the front-end of the industry and still in the incubation stage It is necessary for the pharmaceutical enterprises to strengthen their R & D strength and use their capital to obtain innovation ability, because this is the general trend! 1 Seize innovative resources! There are mainly three types of players in establishing funds to seize innovative resources in the pharmaceutical industry The first is the strong R & D strength, which is expected to connect with international innovation through venture capital; the second is the weak R & D strength, which is built in the form of venture capital; the third is the R & D layout of other subdivisions through the establishment of venture capital In China's pharmaceutical industry, Hengrui has always been known as the benchmark enterprise of local R & D, and also won the title of "the first brother of R & D" In its own R & D strength, Hengrui At the same time, it has not given up the capital means On the one hand, it has covered domestic innovation resources through funds, for example, it has set up Mint capital in cooperation with Wuxi Pharmaceutical Co., Ltd and Xiansheng Pharmaceutical Co., Ltd., and invested in Suzhou intelligent nuclear biology, xinkanghe biological medicine and other enterprises On the other hand, it connects with global innovation through venture capital In May last year, Hengrui, through its holding subsidiary, Hong Kong Ogilvy Health Management Co., Ltd., subscribed its own funds to the shares of the orbited partners, Ltd ClassD fund set up by orbited advisors LLC, and the shares of the orbited private investment VI, LP fund set up by orbited advisors LLC the amount of the subscription amounts are 10 million US dollars each The investment scope of the fund is to make private equity investment or secondary market investment in health industry, including pharmaceuticals, biotechnology, medical enterprises, health services and other health-related fields According to e drug managers, the overall scale of the fund is 3.875 billion yuan In addition to Hengrui pharmaceutical, domestic companies with strong R & D strength are setting up funds in accordance with this path For example, the vivo panda fund with a scale of 103 million yuan was established by Huahai pharmaceutical last year Its main investment goal is an early stage life technology company with explosive potential HISCO also worked with panda health care in Israel last year Ltd has jointly set up HISCO fund, which mainly invests in life science, health care, medical devices and drugs (especially innovative drugs) in cash in Israel; humanwell's 400 million yuan fund mainly invests in innovative biomedicine In the second category, if Fosun Pharmaceutical and Tianshili set up funds, they are more likely to capture R & D resources through capital means because their R & D strength is weak In addition to their existing product lines, it is difficult to quickly build strong R & D capabilities through their own R & D strength in New R & D fields There are many venture capital funds under Fosun Pharmaceutical It's needless to say that the investment of Fosun Hanlin has shown a strong competitive strength in the field of biological medicine, laying a foundation for Fosun's development in this field And Tianshili has invested in innovative drug R & D new star enterprises, such as Xinda biology, Geli biology, Tianjing biology, etc., and has built its own defense line for biological drug R & D The third type is the industrial fund launched to realize the transformation and upgrading of the company In June last year, HongRi Pharmaceutical Co., Ltd set up Beijing Zheyi phase II Industrial Fund with a scale of 211 million yuan The fund not only invests in the direction of industrial strategic integration of listed companies, but also involves in the fields of information technology, environmental protection, new materials, etc.; while zoli Pharmaceutical Co., Ltd and its parent company, zoli group, established a fund with a scale of no more than 200 million yuan, which mainly invests in health services, leisure and health care The 800 million yuan fund established by hiprec mainly focuses on TMT, consumption upgrading, health care and hardware only industries At the beginning of last year, the equity fund of Shanghai Health and medical industry launched by Shanghai Pharmaceutical Co., Ltd focused on the fields of medical e-commerce, new drug research and development, medical devices and medical health ecosystem to drive the development of its own industry 2 in June 2015, Bangjie Co., Ltd set up a fund with the scale of 1 billion yuan Its main investment direction is the large health field, covering the medical service industry, pension service industry, health products (including medicine, diagnosis and treatment equipment, reagents, etc.), internet medical and other multiple industries However, the company is not related to the health industry at all It is an enterprise engaged in seamless clothing design, R & D, manufacturing and marketing Yutong Bus is well known, but last year it also set up a 500 million scale fund, which mainly invests in emerging technology and medical and health enterprises Jinbei Electric is a cable manufacturing enterprise, which is far from medical treatment Last year, it set up a 300 million yuan "Jinbei Zhicheng industry investment fund", which focuses on "large health medical industry and large consumption industry" Stormwind group also set up a 300 million yuan fund last year to include medical and biomedical investment The above-mentioned venture capital fund to enter the field of medical and health care is to fight for the hare, but the main field of Blu ray development is real estate, but the "Ningbo Blu ray PCCW industrial investment fund" invested and set up last year with a scale of 1 billion yuan is totally aimed at the health industry When the fund was set up at that time, it said that on the one hand, it is extended with 3D biological printing; on the other hand, it is consistent with the complex Combined with the development trend of medical industry, and can play the target of upgrading and synergistic effect with the technology and products of 3D bio printing / medical industry of the company Obviously, the enterprises outside the industry have seen the temptation of the industry in the field of health care They hope to quietly enter the industry through the mode of setting up funds With many cross-border funds entering this field, the occupation of innovation resources in the pharmaceutical industry is bound to intensify Who will become the big winner of this round of industrial upgrading with the high cost performance of high-quality innovation resources.